PubReading [7] - Modified nucleic acids: replication, evolution, and next-generation therapeutics - K. Duffy,  S. Arangundy-Franklin and P. Holliger episode artwork

EPISODE · Aug 5, 2021 · 43 MIN

PubReading [7] - Modified nucleic acids: replication, evolution, and next-generation therapeutics - K. Duffy, S. Arangundy-Franklin and P. Holliger

from PubReading

Modified nucleic acids, also called xeno nucleic acids (XNAs), offer a variety of advantages for biotechnological applications and address some of the limitations of first-generation nucleic acid therapeutics. Indeed, several therapeutics based on modified nucleic acids have recently been approved and many more are under clinical evaluation. XNAs can provide increased biostability and furthermore are now increasingly amenable to in vitro evolution, accelerating lead discovery. Here, we review the most recent discoveries in this dynamic field with a focus on progress in the enzymatic replication and functional exploration of XNAs. K. Duffy, S. Arangundy-Franklin and P. Holliger -doi.org/10.1186/s12915-020-00803-6 - 2020

Episode metadata supplied by the publisher feed · Published Aug 5, 2021

Embed this episode

NOW PLAYING

PubReading [7] - Modified nucleic acids: replication, evolution, and next-generation therapeutics - K. Duffy, S. Arangundy-Franklin and P. Holliger

0:00 43:35

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of PubReading?

This episode is 43 minutes long.

When was this PubReading episode published?

This episode was published on August 5, 2021.

Can I download this PubReading episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!